A new therapy to re-engage the heart’s natural electrical pathways – instead of bypassing them – could mean more treatment options for heart failure patients who also suffer from electrical disturbances, such as arrhythmias, according to research led by the University of Chicago Medicine.
In a first-ever pilot study, called the His SYNC trial, researchers compared the effectiveness of two different cardiac resynchronization therapies, or treatments to correct irregularities in the heartbeat through implanted pacemakers and defibrillators. The current standard of care, known as biventricular pacing, uses two pacing impulses in both lower chambers, whereas the newer approach, called His bundle pacing, attempts to work toward engaging and restoring the heart’s natural physiology. The two approaches have never before been directly compared in a head-to-head clinical trial.
“This is the first prospective study in our field to compare outcomes between different ways to achieve cardiac resynchronization,” said cardiologist Roderick Tung, MD, FHRS, the Director of Cardiac Electrophysiology & EP Laboratories at the University of Chicago Medicine. “Through His bundle pacing, we’re trying to tap into the normal wiring of the heart and restore conduction the way nature intended. Previously, we have just accepted that we had to bypass it through pacing two ventricles at a time.”
Tung spearheaded the two-year trial with UChicago Medicine cardiologist Gaurav Upadhyay, MD, FHRS, lead author of the study. The trial involved 40 adult patients across seven institutions in the Midwest. The UChicago Medicine team served as the independent coordinating site. Results of the study were presented as a featured late-breaking trial at the Heart Rhythm Society’s annual scientific sessions in San Francisco on May 9. To qualify as a late-breaking trial, the research must be groundbreaking and unique. The study was also published in the Journal of the American College of Cardiology.
A different resynchronization method
Biventricular pacing involves implanting wires, called leads, to simultaneously pace the right and left ventricles of the heart. A pacemaker then sends a timed electric pulse to the two leads with the goal of a synchronized contraction, which closely simulates the heart’s natural heartbeat.
Nevertheless, roughly 30 percent of patients do not respond to biventricular pacing treatment, which has been shown to improve survival in clinical trials.
Tung’s team looked to see if another resynchronization method could help reduce that number by doing a clinical trial comparison between biventricular pacing and His bundle pacing. The latter involves implanting a single lead at the start of the heart’s wiring system, which then naturally branches in two to organically distribute the pacemaker’s electric pulse to both ventricles.
“Permanent His bundle pacing has been around for almost 20 years, but until now there hasn’t been randomized clinical trials on how it compares to biventricular pacing,” Tung said.
For the His SYNC trial, all of the patients met the current guidelines for receiving cardiac resynchronization therapy and were randomly selected to receive either a His bundle pacer or a coronary sinus lead for biventricular pacing. Patients weren’t told which treatment they received.
While the results of the preliminary study did not demonstrate superiority with His-CRT, Tung and his team believe a His bundle pacing approach showed comparable rates of response, warranting further study. The research was limited by a high crossover rate, which was required by the study’s protocol if an adequate lead placement could not be achieved. Nearly half of the patients selected to receive His bundle pacing had to eventually be treated with traditional biventricular pacing due to having a condition called interventricular conduction delay (IVCD). The implantation tools have also not been refined since their introduction 10 years ago.
“We need to learn how to better identify patients who cannot and will not respond to His bundle pacing,” Tung said. “During this pilot study, we learned that the net was cast too wide, and patients with IVCD can’t be corrected and improved by His bundle pacing. His SYNC II, our planned follow-up study, will specifically exclude these patients and this is perhaps the most valuable lesson from the pilot, in addition to estimated treatment effect size.”
In addition, 26 percent of patients chosen to receive biventricular pacing did not, usually because a lead could not be inserted due to the condition of their veins dictated by strict criteria to optimize implantation of left ventricular leads.
Comparing the two approaches
After six months, researchers compared the electrical synchronization and structural function of the two patient groups’ hearts. Although they expected His bundle pacing to be superior, they found no overall significant differences in the two groups, with comparable rates of electrical resynchronization and echocardiographic response.
After one year, there were no differences in the number of hospitalizations or deaths.
Noting the pilot study was limited by its size, Tung says the results indicate further investigation is needed.
“Pilot studies are never meant to be conclusive,” he said. “They’re meant to inform us about effect size, safety and feasibility to help select appropriate patients and power larger studies.”
The Latest on: Heart failure
[google_news title=”” keyword=”heart failure” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Heart failure
- Advice From Harvard Health Publishing And 3 More Doctors: What Happens If Coronary Artery Disease Is Left Untreated?on December 6, 2023 at 5:51 pm
Answered by Dr. Howard E. Lewine M.D. Chief Medical Editor, Harvard Health Publishing · 40 years of experience · USA Coronary artery disease (CAD) is most often caused by fatty plague buildup in the ...
- Woman Receives Rare Bloodless Heart Transplant in Accordance with Jehovah's Witness Beliefs After Waiting 18 Yearson December 6, 2023 at 5:32 pm
We may not have the same faith or beliefs as they do, but we respect their beliefs," said Dr. Valluvan Jeevanandam, who performed the transplant ...
- BridgeBio Submits FDA Application for Heart Failure Drug Acoramidison December 6, 2023 at 9:57 am
Acoramidis is an oral small molecule to treat patients with transthyretin amyloid cardiomyopathy.
- Eating oily fish may benefit people with family history of heart diseaseon December 6, 2023 at 7:59 am
Folks with a family history of heart disease might benefit from eating more oily fish like salmon, mackerel, herring and sardines, a new study finds.
- Coronary heart disease diagnosis before age 45 may increase dementia risk by 36%on December 6, 2023 at 6:52 am
People who had coronary heart disease before age 45 had a 36% increased risk of developing dementia and a 13% increased risk of developing Alzheimer’s, a new study has found.
- SAXOPHONE Bolsters Apixaban for Pediatric Heart Diseaseon December 5, 2023 at 9:37 am
There were low rates of bleeding and no thromboembolic events with either the DOAC or standard-of-care anticoagulation.
- Rocket Pharma Seeks Gene Therapy Revolution For Genetic Heart Diseaseon December 5, 2023 at 9:34 am
Rocket Pharma has a pipeline of six gene therapy programs addressing cardiovascular and hematology-based diseases at the genetic level.
- Losartan in Heart Failureon December 4, 2023 at 4:00 pm
Background The aim of the present study was to assess the short- and long-term effects of multiple doses of the angiotensin II receptor antagonist losartan in heart failure. Conclusions This study ...
- UK primary care group adopts digital heart failure pathwayon December 4, 2023 at 4:29 am
Widnes Primary Care Network, which is part of NHS Cheshire and Merseyside, said the new initiative will help healthcare professionals identify and recommend digital health apps that can be used at ...
- Heart-in-a-jar: Singapore to bioengineer mini Asian models with heart failure to test drugson December 3, 2023 at 7:12 pm
SINGAPORE: Heart failure is the leading cause of death in Singapore – every day, an average of 34 people have heart attacks and 23 people die from heart disease.
via Bing News